FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab (BV) in the first-line treatment of metastatic colorectal cancer (mCRC): A phase II study by the G.O.N.O. group
2008 ◽
Vol 26
(15_suppl)
◽
pp. 4031-4031
◽
Keyword(s):
Phase Ii
◽
2007 ◽
Vol 96
(3)
◽
pp. 439-444
◽